AZ, Merck add pancreatic cancer to Lynparza’s growing use listAstraZeneca and Merck & Co have cemented their lead in the PARP inhibitor class with FDA approval for Share XAZ, Merck add pancreatic cancer to Lynparza’s growing use listhttps://pharmaphorum.com/news/az-merck-add-pancreatic-cancer-to-lynparzas-growing-use-list/
AZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancerAstraZeneca and Merck & Co are closer to a new use for their PARP inhibitor Lynparza in pancreatic Share XAZ’s Lynparza inches towards ‘game changer’ okay in pancreatic cancerhttps://pharmaphorum.com/news/azs-lynparza-inches-towards-game-changer-okay-in-pancreatic-cancer/
Halozyme abandons cancer R&D as lead drug failedUS biotech Halozyme has been forced to cut more than half its workforce and exit cancer R&D after Share XHalozyme abandons cancer R&D as lead drug failedhttps://pharmaphorum.com/news/halozyme-abandons-cancer-rd-as-lead-drug-failed/
Lilly’s $1.6bn cancer drug draws blank in pancreatic cancer trialEli Lilly is looking at other uses for its new cancer immunotherapy pegilodecakin after it flopped in a Share XLilly’s $1.6bn cancer drug draws blank in pancreatic cancer trialhttps://pharmaphorum.com/news/lillys-1-6bn-cancer-drug-draws-blank-in-pancreatic-cancer-trial/
AZ/Merck & Co wow ASCO with pancreatic cancer dataFinding targeted therapies for pancreatic cancer has long been an issue for pharma, meaning that for decades the Share XAZ/Merck & Co wow ASCO with pancreatic cancer datahttps://pharmaphorum.com/news/az-merck-co-wow-asco-with-pancreatic-cancer-data/
Oncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and moreAZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, Share XOncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and morehttps://pharmaphorum.com/views-and-analysis/oncology-round-up-az-and-daiichi-score-key-trial-win-with-breast-cancer-antibody-and-more/
CRUK tests drug combo for advanced pancreatic cancerCancer Research UK has announced it will study Plexxikon’s dual kinase inhibitor PLX7486 in combination with gemcitabine in Share XCRUK tests drug combo for advanced pancreatic cancerhttps://pharmaphorum.com/news/cruk-tests-drug-combo-for-advanced-pancreatic-cancer/
Clovis’ Rubraca is latest PARP drug showing promise in pancreatic cancerClovis Oncology’s Rubraca has become the latest PARP drug to show potential in pancreatic cancer, as pharma companies Share XClovis’ Rubraca is latest PARP drug showing promise in pancreatic cancerhttps://pharmaphorum.com/news/clovis-rubraca/
AZ/Merck & Co’s Lynparza delays spread of pancreatic cancerAstraZeneca and Merck & Co’s Lynparza could offer a new option for certain patients with pancreatic cancer after Share XAZ/Merck & Co’s Lynparza delays spread of pancreatic cancerhttps://pharmaphorum.com/news/az-merck-cos-lynparza-delays-spread-of-pancreatic-cancer/
